Navigation Links
Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine Comes to the App Store
Date:8/3/2011

PHILADELPHIA, August 3, 2011 /PRNewswire/ --


- Content From the Widely-respected Cardiology Reference Book's Forthcoming Ninth Edition Now Available to Users on iPad, iPhone and iPod Touch


Elsevier, the leading provider of scientific, technical and medical information products and services, announced its Braunwald's Heart Disease Practice Guides App for iPad, iPhone and iPod Touch is now available on the App Store. The app includes content from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Ninth Edition, and provides the most up-to-date, evidence-based cardiology clinical practice guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA).

Braunwald's Heart Disease Practice Guidelines App provides access to the most useful, clinically actionable and evidence-based cardiology clinical practice guidelines today. The joint cardiovascular practice guidelines of the ACC and the AHA have become important documents for guiding cardiology practice and establishing benchmarks for quality of care. In each edition of Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, the market-leading global clinical textbook of cardiology, authors and editors summarize all the latest ACC/AHA practice guidelines and transform them into clinically actionable points presented in an easily accessible, bulleted format. For the first time the guidelines have been streamlined for mobile presentation and are available for download by cardiologists and all related healthcare professionals who want mobile access to this clinically actionable information in a high-yield, bulleted format.

"We wanted to provide cardiologists and healthcare professionals the ability to have the most up-to-date information available right at their fingertips," said Dr. Eugene Braunwald, founding editor and online editor of Braunwald's Heart Disease.  "This app will give clinicians and professionals anytime, anywhere access to this important information so they can continue to provide the best quality of care possible for their patients."

Braunwald's Heart Disease Practice Guidelines App has several features, including:

  • Content from the brand-new, ninth edition of Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine;
  • Content and cases based on the latest published evidence;
  • Clinically actionable points presented in an easily-digested, bulleted format;
  • Easy navigation, searching and browsing options.


Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Ninth Edition features definitive, state-of-the-art answers covering every aspect of contemporary cardiology.  Edited by Drs. Robert Bonow, Douglas Mann, Douglas Zipes, and Peter Libby, the reference applies the most recent knowledge in molecular biology and genetics, imaging, pharmacology, interventional cardiology, electrophysiology, and much more. Additionally, the new edition features online content, including new dynamic cardiac imaging videos, heart sound recordings, and podcasts.

The Braunwald's Heart Disease Practice Guidelines App is available for $24.99 from the App Store on iPad, iPhone and iPod touch, or at http://www.itunes.com/appstore .

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


Media contact
Tom Reller
Vice President Global Corporate Relations, Elsevier
+1-212-462-1912
t.reller@elsevier.com




'/>"/>
SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare to Report Financial Results for Second Quarter of 2011
2. German Patient Surpasses 5 Years of Support on DuraHeart™ Left Ventricular Assist Device
3. TandemHeart Approved for Expanded Reimbursement
4. Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED
5. CardioFocus HeartLight™ Endoscopic Ablation System Enables Treatment of Atrial Fibrillation: Live Case and Abstract Presented at EHRA EUROPACE 2011
6. New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients
7. Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
8. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
9. CardioFocus HeartLight™ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011
10. Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring
11. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):